Results of published studies reporting remission and MRD status after intensive induction and consolidation chemotherapy
| References . | ELN subgroup . | MRD method . | Patient population N . | Rate of CR/CRi . | Rate of MRD negativity in CR/CRi patients . |
|---|---|---|---|---|---|
| Burnett et al47 | Favorable NPM1 | No MRD | 1113 | 85% | - |
| Döhner et al48 Schwoerer et al49 | Favorable NPM1 | qPCR/dPCR | 588 | 86% | 56% |
| Lambert et al50 | Favorable NPM1 | qPCR | 278 | 89.6 | 37% after induction 1; 93% at EOT |
| Krönke et al51 | Favorable NPM1 | qPCR | 245 | 91% | 19% after induction; 45% after EOT (CR) |
| Lambert et al52 | Favorable NPM1 | - | 271 | 87.1% | - |
| Dillon et al53 | Favorable NPM1 | qPCR | 1206 | 82% | 54% (of 107 NPM1 mut. pts) (CR) |
| Balsat et al54 | Favorable NPM1 | qPCR | 229 | 97% | 55% |
| Othman et al55 | Favorable NPM1 | qPCR | 737 | Only CR pts included | 81% (CR) |
| Bataller et al56 | Favorable NPM1 | qPCR | 110 | 91% | 58% (CR) |
| Dillon et al6 | Favorable NPM1 | NGS | 822 | Only CR pts prior to alloHCT included | 84.7% (CR) |
| Bouvier et al57 | Favorable cytogenetics | - | 238 | 91.6% | - |
| Yin et al58 | Favorable CBF | qPCR/dPCR | 278; 163 (t(8;21)) 115 (inv(16)) | t(8;21): 97% inv(16): 92% (CR) | t(8;21): 47% inv(16): 51% (CR) |
| Rücker et al59 | Favorable CBF t(8;21) | qPCR | 155 | 98% | PB 74% EOT; PB 48% after 2 cycles (CR) |
| Borthakur et al60 | Favorable CBF | qPCR | 45 | 95% | 98% |
| Willekens et al61 | Favorable CBF t(8;21) | qPCR | 94 | Only CR pts included | 70% (in PB) at EOT; during FU PB-MRD negativity 81.9% (CR) |
| Krauter et al62 | Favorable CBF | qPCR | 37 | Only CR pts included | 70.3% MRD level <1% (CR) |
| Weisser et al63 | Favorable CBF t(8;21) | qPCR | 45 | 95.5% | Data on below and above median AML1-ETO expression; no cutoff defined |
| Corbacioglu et al64 | Favorable CBF (inv16) | qPCR | 53 | Only CR pts included | 59% (CR) |
| Deotare et al65 | Favorable CBF | qPCR | 80 | 90% | 33% |
| Puckrin et al66 | Favorable CBF | qPCR | 114 | 99.1% (CR) | 72.8% (CR) |
| Marcucci et al67 | Favorable CBF | - | 61 | 90% (CR) | - |
| Paschka et al68 | Favorable CBF | - | 89 | 94% | - |
| Freeman et al69 | NPM1 | MFC | GO1: 100 GO2: 115 | 80% 77% | 62% 70% |
| Freeman et al70 | Favorable (FLT3-ITD wt, NPM1 mut) | MFC | 213 | 88% | 53% |
| Stone et al9 | Intermediate FLT3-ITD | - | 717 | 59% (CR) | - |
| Röllig et al71 | Intermediate FLT3-ITD | - | 267 | 60% (CR) | - |
| Erba et al8 Levis et al72 | Intermediate FLT3-ITD | NGS FLT3-ITD | 539 | 71.6% | 24.6% |
| Grob et al4 | Intermediate FLT3-ITD | NGS FLT3-ITD; MFC (in 138 of 161 pts with FLT3-ITD) | 161 | Only CR pts included | 71% (CR) |
| Loo et al5 | Intermediate FLT3-ITD | NGS | 104 | Only CR pts included | 63.5% (CR) |
| Dillon et al6 | Intermediate FLT3-ITD | NGS | 822 | Only CR pts included | 86% (CR) |
| Han et al73 | Intermediate risk | MFC/LAIP | 235 | 91.5% | 56.6% after cycle 3 |
| Freeman et al74 | Intermediate risk | MFC | 1754 279 with C2 MRD | 65.5% (CR) | 64% (CR) |
| Tettero et al75 | Intermediate risk | MFC; qPCR for NPM1 | 153 | Only CR/CRi patients included | 72% |
| Venditti et al76 | Intermediate risk | MFC; qPCR for CBF and NPM1 | 500 | 72% (CR) | 45% negative by both techniques (CR) |
| Freeman et al69 | FLT3-ITD | MFC | GO1: 80 GO2: 99 | 71% 72% | 59% 58% |
| Freeman et al70 | Intermediate | MFC | 1230 | 68% | 41% |
| Lancet et al77 | Adverse | MFC | 309 | 47.7% | - |
| Rautenberg et al78 | tAML, AML-MRC | MFC | 188 | 47% | 64% |
| Freeman et al70 | MRC | MFC | 246 | 46% | 24% |
| Freeman et al69 | TP53 | MFC | GO1: 32 GO2: 37 | 47% 43% | 22% 23% |
| References . | ELN subgroup . | MRD method . | Patient population N . | Rate of CR/CRi . | Rate of MRD negativity in CR/CRi patients . |
|---|---|---|---|---|---|
| Burnett et al47 | Favorable NPM1 | No MRD | 1113 | 85% | - |
| Döhner et al48 Schwoerer et al49 | Favorable NPM1 | qPCR/dPCR | 588 | 86% | 56% |
| Lambert et al50 | Favorable NPM1 | qPCR | 278 | 89.6 | 37% after induction 1; 93% at EOT |
| Krönke et al51 | Favorable NPM1 | qPCR | 245 | 91% | 19% after induction; 45% after EOT (CR) |
| Lambert et al52 | Favorable NPM1 | - | 271 | 87.1% | - |
| Dillon et al53 | Favorable NPM1 | qPCR | 1206 | 82% | 54% (of 107 NPM1 mut. pts) (CR) |
| Balsat et al54 | Favorable NPM1 | qPCR | 229 | 97% | 55% |
| Othman et al55 | Favorable NPM1 | qPCR | 737 | Only CR pts included | 81% (CR) |
| Bataller et al56 | Favorable NPM1 | qPCR | 110 | 91% | 58% (CR) |
| Dillon et al6 | Favorable NPM1 | NGS | 822 | Only CR pts prior to alloHCT included | 84.7% (CR) |
| Bouvier et al57 | Favorable cytogenetics | - | 238 | 91.6% | - |
| Yin et al58 | Favorable CBF | qPCR/dPCR | 278; 163 (t(8;21)) 115 (inv(16)) | t(8;21): 97% inv(16): 92% (CR) | t(8;21): 47% inv(16): 51% (CR) |
| Rücker et al59 | Favorable CBF t(8;21) | qPCR | 155 | 98% | PB 74% EOT; PB 48% after 2 cycles (CR) |
| Borthakur et al60 | Favorable CBF | qPCR | 45 | 95% | 98% |
| Willekens et al61 | Favorable CBF t(8;21) | qPCR | 94 | Only CR pts included | 70% (in PB) at EOT; during FU PB-MRD negativity 81.9% (CR) |
| Krauter et al62 | Favorable CBF | qPCR | 37 | Only CR pts included | 70.3% MRD level <1% (CR) |
| Weisser et al63 | Favorable CBF t(8;21) | qPCR | 45 | 95.5% | Data on below and above median AML1-ETO expression; no cutoff defined |
| Corbacioglu et al64 | Favorable CBF (inv16) | qPCR | 53 | Only CR pts included | 59% (CR) |
| Deotare et al65 | Favorable CBF | qPCR | 80 | 90% | 33% |
| Puckrin et al66 | Favorable CBF | qPCR | 114 | 99.1% (CR) | 72.8% (CR) |
| Marcucci et al67 | Favorable CBF | - | 61 | 90% (CR) | - |
| Paschka et al68 | Favorable CBF | - | 89 | 94% | - |
| Freeman et al69 | NPM1 | MFC | GO1: 100 GO2: 115 | 80% 77% | 62% 70% |
| Freeman et al70 | Favorable (FLT3-ITD wt, NPM1 mut) | MFC | 213 | 88% | 53% |
| Stone et al9 | Intermediate FLT3-ITD | - | 717 | 59% (CR) | - |
| Röllig et al71 | Intermediate FLT3-ITD | - | 267 | 60% (CR) | - |
| Erba et al8 Levis et al72 | Intermediate FLT3-ITD | NGS FLT3-ITD | 539 | 71.6% | 24.6% |
| Grob et al4 | Intermediate FLT3-ITD | NGS FLT3-ITD; MFC (in 138 of 161 pts with FLT3-ITD) | 161 | Only CR pts included | 71% (CR) |
| Loo et al5 | Intermediate FLT3-ITD | NGS | 104 | Only CR pts included | 63.5% (CR) |
| Dillon et al6 | Intermediate FLT3-ITD | NGS | 822 | Only CR pts included | 86% (CR) |
| Han et al73 | Intermediate risk | MFC/LAIP | 235 | 91.5% | 56.6% after cycle 3 |
| Freeman et al74 | Intermediate risk | MFC | 1754 279 with C2 MRD | 65.5% (CR) | 64% (CR) |
| Tettero et al75 | Intermediate risk | MFC; qPCR for NPM1 | 153 | Only CR/CRi patients included | 72% |
| Venditti et al76 | Intermediate risk | MFC; qPCR for CBF and NPM1 | 500 | 72% (CR) | 45% negative by both techniques (CR) |
| Freeman et al69 | FLT3-ITD | MFC | GO1: 80 GO2: 99 | 71% 72% | 59% 58% |
| Freeman et al70 | Intermediate | MFC | 1230 | 68% | 41% |
| Lancet et al77 | Adverse | MFC | 309 | 47.7% | - |
| Rautenberg et al78 | tAML, AML-MRC | MFC | 188 | 47% | 64% |
| Freeman et al70 | MRC | MFC | 246 | 46% | 24% |
| Freeman et al69 | TP53 | MFC | GO1: 32 GO2: 37 | 47% 43% | 22% 23% |
CBF, core binding factor; dPCR, digital PCR; EOT, end of treatment; FU, follow-up; GO, gemtuzumab ozogamicin; inv, inversion, PB, peripheral blood; pts, patients; t, translocation; tAML, therapy-related AML (acute myeloid leukemia).